RESUMEN
Some organophosphorus compounds can cause organophosphate-induced delayed neuropathy (OPIDN). Incidents have been documented for decades, however, little is known about which proteins contribute to the initiation, progression and development of OPIDN. In this study, 51 hens were divided into three groups. The tri-ortho-cresyl-phosphate (TOCP) group was treated with 1000 mg kg(-1) TOCP whereas the control group was treated with an equivalent volume of vehicle. The PMSF + TOCP group was treated subcutaneously with 40 mg kg(-1) phenylmethylsulfonyl fluoride (PMSF), followed by 1000 mg kg(-1) TOCP 24 h later. Proteins in the brains of hens were separated by two-dimensional polyacrylamide gel electrophoresis on day 5 after TOCP administration. Mass spectrometry identified eight differentially expressed proteins. Among these proteins, downregulated expression of glutamine synthetase (GS) in the brains of hens after TOCP treatment was further confirmed by real time RT-PCR and ELISA. Moreover, the brains of hens exposed to TOCP exhibited increased levels of glutamate (Glu) and cytosolic calcium concentration ([Ca(2+)](i)), and a decreased level of glutamine (Gln). However, there were no significant differences in GS expression or levels of Glu, Gln, and [Ca(2+)](i) in the brains of hens among the groups on day 21 after TOCP administration. These results indicate that TOCP exposure downregulates GS expression in the brains of hens, and that downregulation of GS is accompanied by increased levels of Glu and [Ca(2+)](i) in the early stage after TOCP administration. It is also suggested that the downregulated expression of GS might be associated with OPIDN through the disruption of homeostasis of the Glu-Gln cycle and [Ca(2+) ](i).
Asunto(s)
Encéfalo/efectos de los fármacos , Glutamato-Amoníaco Ligasa/biosíntesis , Síndromes de Neurotoxicidad/metabolismo , Compuestos Organofosforados/toxicidad , Biosíntesis de Proteínas/efectos de los fármacos , Animales , Conducta Animal/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/patología , Calcio/metabolismo , Pollos , Citosol/efectos de los fármacos , Citosol/metabolismo , Regulación hacia Abajo , Ensayo de Inmunoadsorción Enzimática , Glutamatos/metabolismo , Síndromes de Neurotoxicidad/etiología , Síndromes de Neurotoxicidad/patología , Síndromes de Neurotoxicidad/prevención & control , Compuestos Organofosforados/química , Fluoruro de Fenilmetilsulfonilo/administración & dosificación , Fluoruro de Fenilmetilsulfonilo/uso terapéutico , Reacción en Cadena en Tiempo Real de la Polimerasa , Factores de TiempoRESUMEN
Hens injected in one sciatic artery with diisopropylfluorophosphate (DFP) (0.184 mg/kg) developed monolateral ataxia on the injected side 10-12 days later. The inhibition of neuropathy target esterase (NTE) was 85% in the sciatic nerve of the injected leg and less than 60% in the contralateral sciatic nerve, in spinal cord and in brain. Other hens injected in the wing vein with the same dose of DFP showed low inhibition of NTE in the nervous system and did not develop delayed neuropathy. Hens injected in one sciatic artery with phenylmethanesulphonyl fluoride (PMSF) (1 mg/kg) and 24 hr later with high subcutaneous dose of DFP (1.1 mg/kg) developed monolateral ataxia 10-12 days later on the side not injected with PMSF. The level of NTE inhibition after PMSF was greater than 40% in the sciatic nerve on the injected side compared with less than 20% in other parts of the nervous system. The same dose of PMSF injected in the wing vein produced low NTE inhibition in the nervous system and failed to protect the animals from the same high systemic dose of DFP. We conclude that both toxic and protective effects of NTE inhibitors for delayed neuropathy are better related to the level of NTE inhibition in the peripheral nerve on the site of injection than to NTE inhibition in other parts of the nervous system. Furthermore we suggest that NTE inhibition should also be measured in the peripheral nerve in the standard toxicity testing for organophosphate-induced delayed neurotoxicity.
Asunto(s)
Hidrolasas de Éster Carboxílico/antagonistas & inhibidores , Isoflurofato/toxicidad , Enfermedades del Sistema Nervioso/inducido químicamente , Fluoruro de Fenilmetilsulfonilo/farmacología , Sulfonas/farmacología , Animales , Pollos , Femenino , Inyecciones Intraarteriales , Isoflurofato/administración & dosificación , Sistema Nervioso/enzimología , Enfermedades del Sistema Nervioso/prevención & control , Fluoruro de Fenilmetilsulfonilo/administración & dosificaciónRESUMEN
This paper reports studies in hens showing that diisopropyl phosphorofluoridate (DFP) neuropathy is promoted by PMSF when initiated either in central (spinal cord) or peripheral nervous system. Moreover, the critical site for promotion is in peripheral nerve axons rather than in their cell bodies. Selective promotion in peripheral nerves was achieved by giving PMSF into sciatic artery monolaterally (7 mg/kg) to birds where neuropathy was initiated by DFP, either systematically (0.3 mg/kg s.c.) or intra-arterially (0.04 mg/kg in the same artery). Birds developed monolateral neuropathy in the leg where PMSF was delivered. Promotion of spinal cord neuropathy was achieved by giving PMSF (120 mg/kg s.c.) to birds where neuropathy was initiated selectively in spinal cord. This was obtained by protecting peripheral axons with intra-arterial bilateral injections of PMSF (0.55 x 2 mg/kg) followed by DFP (0.3, 0.4 or 0.7 mg/kg s.c.). The resulting syndrome was characterized by spastic ataxia.
Asunto(s)
Isoflurofato/toxicidad , Enfermedades del Sistema Nervioso Periférico/inducido químicamente , Fluoruro de Fenilmetilsulfonilo/toxicidad , Enfermedades de la Médula Espinal/inducido químicamente , Animales , Ataxia/inducido químicamente , Axones/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Hidrolasas de Éster Carboxílico/antagonistas & inhibidores , Pollos , Interacciones Farmacológicas , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/toxicidad , Femenino , Isoflurofato/administración & dosificación , Nervios Periféricos/efectos de los fármacos , Nervios Periféricos/enzimología , Fluoruro de Fenilmetilsulfonilo/administración & dosificación , Médula Espinal/efectos de los fármacos , Médula Espinal/enzimologíaRESUMEN
Endogenous cannabinoid ligands and cannabinoid CB1 receptor agonists have been shown to exert anticonvulsant effects in various experimental models of epilepsy. The purpose of this study was to determine the effects of arachidonyl-2'-chloroethylamide (ACEA-a highly selective cannabinoid CB1 receptor agonist) on the protective action of clonazepam, ethosuximide, phenobarbital, and valproate against pentylenetetrazole (PTZ)-induced clonic seizures in mice. To ascertain any pharmacokinetic contribution of ACEA to the observed interactions between tested drugs, free (non-protein bound) plasma and total brain concentrations of the antiepileptic drugs were estimated. Additionally, acute adverse-effect profiles of the combination of ACEA and different classical antiepileptic drugs (clonazepam, ethosuximide, phenobarbital and valproate) with respect to motor performance, long-term memory and skeletal muscular strength were measured. Results indicated that ACEA (10mg/kg, i.p.) co-administered with phenylmethylsulfonyl fluoride (PMSF-a substance protecting ACEA against degradation by the fatty-acid hydrolase; 30mg/kg, i.p.) significantly potentiated the anticonvulsant activity of ethosuximide, phenobarbital and valproate in the mouse PTZ-induced clonic seizure model by reducing their median effective doses (ED(50) values) from 122.8mg/kg to 71.7mg/kg (P<0.01; for ethosuximide), from 13.77mg/kg to 5.26mg/kg (P<0.05; for phenobarbital), and from 142.7mg/kg to 87.3mg/kg (P<0.05; for valproate), respectively. In contrast, ACEA (10mg/kg, i.p.) in combination with PMSF (30mg/kg, i.p.) had no impact on the protective action of clonazepam against PTZ-induced seizures in mice. However, ACEA (10mg/kg)+PMSF (30mg/kg) considerably increased free plasma and total brain concentrations of ethosuximide and valproate in mice suggesting a pharmacokinetic nature of interaction between drugs. In contrast, free plasma and total brain concentrations of clonazepam and phenobarbital remained unchanged after ACEA+PMSF administration and thus, indicating pharmacodynamic interactions. Moreover, none of the examined combinations of ACEA (10mg/kg, i.p.)+PMSF (30mg/kg, i.p.) with clonazepam, ethosuximide, phenobarbital, and valproate (at their ED(50) values from the PTZ-induced seizure test) affected motor coordination in the chimney test, long-term memory in the passive avoidance task, and muscular strength in the grip-strength test in mice, indicating no possible acute adverse effects in animals. In conclusion, pharmacodynamic enhancement of the anticonvulsant potency of phenobarbital by ACEA+PMSF is worthy of recommendation for further clinical settings. Pharmacokinetic interactions of ACEA+PMSF with ethosuximide and valproate seem to be responsible for a significant suppression of PTZ-induced seizures in mice. The combination of ACEA+PMSF with clonazepam seems to be neutral from a preclinical viewpoint.
Asunto(s)
Anticonvulsivantes/farmacología , Ácidos Araquidónicos/farmacología , Agonistas de Receptores de Cannabinoides/farmacología , Convulsiones/tratamiento farmacológico , Animales , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/farmacocinética , Anticonvulsivantes/uso terapéutico , Ácidos Araquidónicos/administración & dosificación , Ácidos Araquidónicos/uso terapéutico , Reacción de Prevención/efectos de los fármacos , Agonistas de Receptores de Cannabinoides/uso terapéutico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Quimioterapia Combinada/efectos adversos , Fuerza de la Mano , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Pentilenotetrazol , Fluoruro de Fenilmetilsulfonilo/administración & dosificaciónRESUMEN
Neuropathy target esterase (NTE) is proven to act as a lysophospholipase (LysoPLA) in mice and phospholipase B (PLB) in cultured mammalian cells. In sensitive species, organophosphate (OP)-induced delayed neurotoxicity is initiated when NTE is inhibited by > 70% and then aged. It is hypothesized that homeostasis of phosphatidylcholine (PC) and/or lysophosphatidylcholine (LPC) in mice might be disrupted by the OPs since NTE and other phospholipases could be inhibited. To test this hypothesis, we treated mice using tri-o-cresyl phosphate (TOCP), which can inhibit and age NTE. Phenylmethylsulfonyl fluoride (PMSF), which inhibits NTE but cannot age, was used as a negative control. Effects on activity of NTE, LysoPLA, and PLB, the levels of PC, LPC, and glycerophosphocholine (GPC), and the aging of NTE in the brain, spinal cord, and sciatic nerve were examined. The results showed that the activities of NTE, NTE-LysoPLA, LysoPLA, NTE-PLB, and PLB were significantly inhibited in both TOCP- and PMSF-treated mice, and the inhibition of NTE and NTE-LysoPLA or NTE-PLB showed a high correlation coefficient. The NTE inhibited by TOCP was of the aged type, while nearly all NTE inhibited by PMSF was of the unaged type. Although the GPC level was remarkedly decreased, no significant change of PC and LPC levels was observed. However, the inhibition of these enzymes in mice by TOCP exhibited different characteristics from the TOCP-treated hens that we previously reported, which indicates that these enzymes were inhibited and then recovered more rapidly in mice than in hens. All results suggest that PC and LPC homeostasis was not disrupted in mice after exposure to TOCP. Differences in inhibition of NTE, LysoPLA, and PLB activities by TOCP between mice and hens may elucidate why these two species display different signs after exposure to the same neuropathic OPs.
Asunto(s)
Hidrolasas de Éster Carboxílico/metabolismo , Homeostasis/efectos de los fármacos , Lisofosfatidilcolinas/metabolismo , Fosfatidilcolinas/metabolismo , Tritolilfosfatos/toxicidad , Análisis de Varianza , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Hidrolasas de Éster Carboxílico/efectos de los fármacos , Lisofosfolipasa/metabolismo , Masculino , Ratones , Síndromes de Neurotoxicidad/metabolismo , Fluoruro de Fenilmetilsulfonilo/administración & dosificación , Fluoruro de Fenilmetilsulfonilo/toxicidad , Fosforilación/efectos de los fármacos , Nervio Ciático/efectos de los fármacos , Nervio Ciático/metabolismo , Médula Espinal/efectos de los fármacos , Médula Espinal/metabolismo , Tritolilfosfatos/administración & dosificaciónRESUMEN
Some empirical evidence suggests that the endocannabinoids (eCB) (e.g. anandamide) may play an important role in cocaine addiction. The eCB act as a retrograde messengers activating CB receptors at the presynaptic membrane and are degraded by enzymatic actions of fatty acid amide hydrolase (FAAH). The present study aimed to examine the effect of the FAAH inhibitors, phenylmethylsulphonyl fluoride (PMSF; i.p.) or cyclohexylcarbamic acid 3-carbamoyl biphenyl-3-yl ester (URB597; i.p.) on the cocaine- or food-maintained self-administration as well as on the cocaine-seeking or food-taking behaviors in rats. Male Wistar rats were implanted with a catheter (iv.) and trained to self-administer cocaine (0.5 mg/kg/infusion) on a fixed ratio 5 schedule of reinforcement with a conditioned stimulus (tone+light). After self-administration stabilized, extinction/reinstatement procedures were carried out during which the rats were tested for the response reinstatement induced by cocaine (10 mg/kg, ip) or a cue (light+tone). The food (sweetened milk) self-administration and extinction/reinstatement procedures were conducted in a manner resembling cocaine self-administration. Neither PMSF (30-120 mg/kg) nor URB597 (0.1-3 mg/kg) affected cocaine self-administration. PMSF, 60 mg/kg, significantly reduced cocaine-induced reinstatement and at 120 mg/kg (combined with the challenge dose of cocaine) it evoked behavioral disruption. PMSF (60-120 mg/kg) dose-dependently inhibited cue-induced reinstatement. URB597 (1-3 mg/kg) attenuated both cocaine- and cue-induced drug-seeking behaviors. PMSF (60 mg/kg) decreased food self-administration. Toward reinstatement of food-taking behavior PMSF (60-120 mg/kg) and URB597 (3 mg/kg) showed inhibitory effects. Our results indicate that FAAH inhibitors could be potent modulators of motivational and conditioned aspects of goal-directed behaviors with less prominent effects on consumatory behaviors.
Asunto(s)
Amidohidrolasas/antagonistas & inhibidores , Conducta Animal/efectos de los fármacos , Trastornos Relacionados con Cocaína/psicología , Cocaína/administración & dosificación , Ingestión de Alimentos/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Refuerzo en Psicología , Animales , Benzamidas/administración & dosificación , Benzamidas/farmacología , Carbamatos/administración & dosificación , Carbamatos/farmacología , Trastornos Relacionados con Cocaína/enzimología , Trastornos Relacionados con Cocaína/metabolismo , Conducta Consumatoria/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/administración & dosificación , Extinción Psicológica/efectos de los fármacos , Conducta Alimentaria/efectos de los fármacos , Inyecciones Intraperitoneales , Masculino , Fluoruro de Fenilmetilsulfonilo/administración & dosificación , Fluoruro de Fenilmetilsulfonilo/farmacología , Ratas , Ratas Wistar , AutoadministraciónRESUMEN
A fluorimetric determination method for N-arachidonoylethanolamine (anandamide) was developed using a precolumn fluorescence derivatization followed by coupled-column high-performance liquid chromatography (HPLC). Anandamide extracted from the rat brain tissue was derivatized with 4-N-chloroformylmethyl-N-methylamino-7-N, N-dimethylaminosulfonyl-2,1,3-benzoxadiazole (DBD-COCl), purified by a solid-phase extraction (Emporetrade mark), and assayed by the coupled-column HPLC. The HPLC consisted of phenyl (100 x 4.6 mm i.d. ) and octadecylsilica columns (250 x 4.6 mm i.d.), both connected by a six-port valve. The concentration of anandamide in rat brain was 3. 37 +/- 0.73 pmol/g with 6.47 and 3.57% of intra- and inter-day precisions, respectively. Using this method, we investigated the alteration of anandamide concentration in rat brain 30 min after administration of anandamide (2 mg/kg, i.p.) to rats pretreated with or without phenylmethylsulfonyl fluoride (PMSF; 30 mg/kg, i.p.), an inhibitor of amidohydrolase. In rats pretreated with PMSF, the brain concentration of anandamide was approx. 16-fold higher than that of rats without PMSF (p < 0.01).
Asunto(s)
Ácidos Araquidónicos/análisis , Química Encefálica , Cromatografía Líquida de Alta Presión/métodos , Animales , Endocannabinoides , Masculino , Fluoruro de Fenilmetilsulfonilo/administración & dosificación , Alcamidas Poliinsaturadas , Ratas , Ratas Sprague-Dawley , Espectrometría de FluorescenciaRESUMEN
Some characteristics of the blood coagulation system were analyzed after injection to rats of hirudin-thrombin and phenylmethylsulfonyl-thrombin devoid of clotting and esterase activities because of the blocking of the substrate binding or catalytic site of the active center. Unlike native thrombin, both forms of modified thrombin did not activate the anticoagulation system.
Asunto(s)
Coagulación Sanguínea/efectos de los fármacos , Hirudinas/administración & dosificación , Fluoruro de Fenilmetilsulfonilo/administración & dosificación , Sulfonas/administración & dosificación , Trombina/administración & dosificación , Animales , Sitios de Unión , Dicroismo Circular , Interacciones Farmacológicas , Masculino , RatasRESUMEN
A putative precursor protein for macrophage-chemotactic factor, which was extracted fro inflammatory skin sites (MCFS-1) (Kambara et al, Am J Pathol 1977, 87:359-374), was found in normal guinea pig plasma and was purified to an apparent homogeneity upon SDS-polyacrylamide gel electrophoresis with a molecular weight of 160,000. This plasma protein was different from complement components of C3 and C5 in terms of molecular weight, functional activity as complements detected by hemolytic assay, and immunologic properties. Although it exhibited the common antigenicity with MCFS-1, it did not show any chemotactic activity for macrophages, However, incubation of this plasma protein at either 4 C for 5 days or 37 C for 1-2 days could generate a chemotactic factor with a molecular weight of approximately 150,000 which was similar to that of MCFS-1. This generation of chemotactic activity was completely prevented by the presence of the serine-type protease inhibitor, phenylmethylsulfonyl fluoride. These data could be well accounted for if we assume that this plasma protein might be a precursor for the macrophage-chemotactic factor found in delayed hypersensitivity skin sites, and that a proteolytic process might be involved in the activation of this precursor.
Asunto(s)
Factores Quimiotácticos/sangre , Hipersensibilidad Tardía , Macrófagos , Precursores de Proteínas/aislamiento & purificación , Piel/análisis , Animales , Factores Quimiotácticos/biosíntesis , Factores Quimiotácticos/inmunología , Cromatografía , Electroforesis en Gel de Poliacrilamida , Cobayas , Peso Molecular , Fluoruro de Fenilmetilsulfonilo/administración & dosificación , Precursores de Proteínas/inmunologíaRESUMEN
Certain sulfonates, like phenylmethanesulfonyl fluoride (PMSF), carbamates, and phosphinates, when given prior to neuropathic doses of organophosphates such as diisopropyl phosphorofluoridate (DFP), protect hens from organophosphate-induced delayed polyneuropathy (OPIDP). Protection was related to inhibition of the putative target of OPIDP, which is called Neuropathy Target Esterase (NTE). NTE inhibition above 70-80% in the nervous system of hens followed by a molecular rearrangement called aging initiates OPIDP. PMSF and other protective chemicals inhibit NTE but OPIDP does not develop because aging cannot occur. DFP (1 mg/kg sc) inhibited NTE above 70-80% in peripheral nerve and caused OPIDP in hens. Lower doses (0.3 and 0.5 mg/kg sc) caused about 40-60% NTE inhibition and no or marginal OPIDP. Chlorpyrifos (90 mg/kg po) also caused OPIDP. When repeated (30 mg/kg sc daily for 9 days) or single (5-120 mg/kg sc) doses of PMSF were given after either DFP or chlorpyrifos, OPIDP developed in birds treated with nonneuropathic doses of DFP and was more severe in birds treated with chlorpyrifos or higher doses of DFP. PMSF increased NTE inhibition to greater than 90%. Promotion of OPIDP with a single dose of PMSF (120 mg/kg sc) was obtained in birds up to 11 days after a marginally neuropathic dose of DFP (0.5 mg/kg sc). Promotion was also obtained with phenyl N-methyl N-benzyl carbamate (40 mg/kg iv) but not with non-NTE inhibitors in vivo such as paraoxon or benzenesulfonyl fluoride when given at maximum tolerated doses. These results indicate that protection from OPIDP is only one effect of PMSF because promotion of OPIDP is also observed depending upon the sequence of dosing. Either effect is always related to the doses of PMSF, which inhibit NTE.
Asunto(s)
Enfermedades del Sistema Nervioso/inducido químicamente , Compuestos Organofosforados/toxicidad , Fluoruro de Fenilmetilsulfonilo/toxicidad , Animales , Carbamatos/toxicidad , Hidrolasas de Éster Carboxílico/antagonistas & inhibidores , Pollos , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Femenino , Isoflurofato/administración & dosificación , Isoflurofato/toxicidad , Compuestos Organofosforados/administración & dosificación , Fluoruro de Fenilmetilsulfonilo/administración & dosificación , Relación Estructura-Actividad , Factores de TiempoRESUMEN
It is well known that pretreatment with the serine esterase inhibitor phenylmethylsulfonyl fluoride (PMSF) can protect experimental animals from organophosphorus-induced delayed neurotoxicity (OPIDN), presumably by blocking the active site of neurotoxic esterase (NTE) such that binding and "aging" of the neuropathic OP is thwarted. We report here that while PMSF (60 mg/kg, sc) given 4 h before the neuropathic organophosphate (OP) mipafox (50 mg/kg, im) completely prevented the clinical expression of OPIDN in hens, the identical PMSF treatment markedly amplified the delayed neurotoxicity (relative to hens treated with OP only) if administered 4 h after mipafox (5 or 50 mg/kg, im). Moreover, in a separate experiment using diisopropylphosphorofluoridate (DFP) as the neurotoxicant in place of mipafox, posttreatment with PMSF 4 h after DFP (0.5 mg/kg) also accentuated the severity of ataxia. These data indicate that PMSF only protects against OPIDN if given prior to exposure to the neurotoxicant; treatment with PMSF after OP exposure critically exacerbates the delayed neurotoxicity from exposure to organophosphorus compounds.
Asunto(s)
Isoflurofato/análogos & derivados , Isoflurofato/toxicidad , Sistema Nervioso/efectos de los fármacos , Fluoruro de Fenilmetilsulfonilo/farmacología , Animales , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Hidrolasas de Éster Carboxílico/antagonistas & inhibidores , Pollos , Sinergismo Farmacológico , Femenino , Isoflurofato/antagonistas & inhibidores , Sistema Nervioso/enzimología , Fluoruro de Fenilmetilsulfonilo/administración & dosificación , Nervio Ciático/efectos de los fármacos , Nervio Ciático/enzimología , Médula Espinal/efectos de los fármacos , Médula Espinal/enzimologíaRESUMEN
We previously reported that phenylmethylsulfonyl fluoride (PMSF) administration to rats (100 mg/kg, ip in olive oil) as late as 6 or 10 hr after CCl4 (1 ml/kg, ip as a 20% v/v solution in olive oil) can partially prevent the necrogenic response to the hepatotoxin at 24 hr. Here we confirm that observation by electron microscopy and provide further evidence that only in these circumstances were nuclear clumping of chromatin, slight dilatation of the endoplasmic reticulum, myelin figures and lipid droplets in the cytoplasm, large numbers of lysosomes and peroxisomes, glycogen, and slightly swollen mitochondria observable in the protected animals. A very minor part of the late protective effects of PMSF might be due to the effects of this drug on decreasing the intensity of covalent binding of CCl4-reactive metabolites or the intensity of CCl4-induced lipid peroxidation still occurring 6 or 10 hr after CCl4. PMSF administration did not prevent CCl4-induced decreases in cytochrome P450 content or glucose-6-phosphatase activity but partially prevented CCl4-induced calcium accumulation in liver. PMSF treatment increased glutathione and glycogen content in CCl4-poisoned animals, but did not markedly modify protein/phospholipid synthesis or degradation processes. Results suggest that the late protective effects of PMSF administration in CCl4-induced liver necrosis might be due to a favorable modulation of the calcium-calmodulin system similar to that previously described for other drugs.